Selected research
Industry Research
Metastatic Melanoma Drug Industry Research Report 2026
Market perspective
The global Metastatic Melanoma Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Metastatic Melanoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Metastatic Melanoma Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Metastatic Melanoma Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Metastatic Melanoma Drug include Novartis AG, Merck & Co., Inc., Pfizer Inc., Plexxikon Inc., Philogen S.p.A., Pharmis Biofarmaceutica, Lda., Ono Pharmaceutical Co., Ltd., OncoSec Medical Inc. and Oncolytics Biotech Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Metastatic Melanoma Drug market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Metastatic Melanoma Drug Market by Company
Novartis AG
Merck & Co., Inc.
Pfizer Inc.
Plexxikon Inc.
Philogen S.p.A.
Pharmis Biofarmaceutica, Lda.
Ono Pharmaceutical Co., Ltd.
OncoSec Medical Inc.
Oncolytics Biotech Inc.
Omeros Corporation
NewLink Genetics Corporation
Morphotek, Inc.
Millennium Pharmaceuticals, Inc.
Merck KGaA
Metastatic Melanoma Drug Segment by Type
AGI-134
ALT-801
ALT-803
AMG-232
Others
Metastatic Melanoma Drug Segment by Application
Hospital
Clinic
Others
Metastatic Melanoma Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metastatic Melanoma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Metastatic Melanoma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metastatic Melanoma Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Metastatic Melanoma Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Metastatic Melanoma Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Metastatic Melanoma Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- AGI-134
- ALT-801
- ALT-803
- AMG-232
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Novartis AG
- Merck & Co., Inc.
- Pfizer Inc.
- Plexxikon Inc.
- Philogen S.p.A.
- Pharmis Biofarmaceutica, Lda.
- Ono Pharmaceutical Co., Ltd.
- OncoSec Medical Inc.
- Oncolytics Biotech Inc.
- Omeros Corporation
- NewLink Genetics Corporation
- Morphotek, Inc.
- Millennium Pharmaceuticals, Inc.
- Merck KGaA
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Metastatic Melanoma Drug Market Size (2021-2032)
- 2.2.2 Global Metastatic Melanoma Drug Sales (2021-2032)
- 2.2.3 Global Metastatic Melanoma Drug Market Average Price (2021-2032)
- 2.3 Metastatic Melanoma Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 AGI-134
- 2.3.3 ALT-801
- 2.3.4 ALT-803
- 2.3.5 AMG-232
- 2.3.6 Others
- 2.4 Metastatic Melanoma Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Metastatic Melanoma Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Metastatic Melanoma Drug Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Metastatic Melanoma Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Metastatic Melanoma Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Metastatic Melanoma Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Metastatic Melanoma Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Metastatic Melanoma Drug, Product Type & Application
- 3.8 Global Manufacturers of Metastatic Melanoma Drug, Established Date
- 3.9 Global Metastatic Melanoma Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis AG
- 4.1.1 Novartis AG Company Information
- 4.1.2 Novartis AG Business Overview
- 4.1.3 Novartis AG Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis AG Metastatic Melanoma Drug Product Portfolio
- 4.1.5 Novartis AG Recent Developments
- 4.2 Merck & Co., Inc.
- 4.2.1 Merck & Co., Inc. Company Information
- 4.2.2 Merck & Co., Inc. Business Overview
- 4.2.3 Merck & Co., Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Merck & Co., Inc. Metastatic Melanoma Drug Product Portfolio
- 4.2.5 Merck & Co., Inc. Recent Developments
- 4.3 Pfizer Inc.
- 4.3.1 Pfizer Inc. Company Information
- 4.3.2 Pfizer Inc. Business Overview
- 4.3.3 Pfizer Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pfizer Inc. Metastatic Melanoma Drug Product Portfolio
- 4.3.5 Pfizer Inc. Recent Developments
- 4.4 Plexxikon Inc.
- 4.4.1 Plexxikon Inc. Company Information
- 4.4.2 Plexxikon Inc. Business Overview
- 4.4.3 Plexxikon Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Plexxikon Inc. Metastatic Melanoma Drug Product Portfolio
- 4.4.5 Plexxikon Inc. Recent Developments
- 4.5 Philogen S.p.A.
- 4.5.1 Philogen S.p.A. Company Information
- 4.5.2 Philogen S.p.A. Business Overview
- 4.5.3 Philogen S.p.A. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Philogen S.p.A. Metastatic Melanoma Drug Product Portfolio
- 4.5.5 Philogen S.p.A. Recent Developments
- 4.6 Pharmis Biofarmaceutica, Lda.
- 4.6.1 Pharmis Biofarmaceutica, Lda. Company Information
- 4.6.2 Pharmis Biofarmaceutica, Lda. Business Overview
- 4.6.3 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pharmis Biofarmaceutica, Lda. Metastatic Melanoma Drug Product Portfolio
- 4.6.5 Pharmis Biofarmaceutica, Lda. Recent Developments
- 4.7 Ono Pharmaceutical Co., Ltd.
- 4.7.1 Ono Pharmaceutical Co., Ltd. Company Information
- 4.7.2 Ono Pharmaceutical Co., Ltd. Business Overview
- 4.7.3 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Ono Pharmaceutical Co., Ltd. Metastatic Melanoma Drug Product Portfolio
- 4.7.5 Ono Pharmaceutical Co., Ltd. Recent Developments
- 4.8 OncoSec Medical Inc.
- 4.8.1 OncoSec Medical Inc. Company Information
- 4.8.2 OncoSec Medical Inc. Business Overview
- 4.8.3 OncoSec Medical Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 OncoSec Medical Inc. Metastatic Melanoma Drug Product Portfolio
- 4.8.5 OncoSec Medical Inc. Recent Developments
- 4.9 Oncolytics Biotech Inc.
- 4.9.1 Oncolytics Biotech Inc. Company Information
- 4.9.2 Oncolytics Biotech Inc. Business Overview
- 4.9.3 Oncolytics Biotech Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Oncolytics Biotech Inc. Metastatic Melanoma Drug Product Portfolio
- 4.9.5 Oncolytics Biotech Inc. Recent Developments
- 4.10 Omeros Corporation
- 4.10.1 Omeros Corporation Company Information
- 4.10.2 Omeros Corporation Business Overview
- 4.10.3 Omeros Corporation Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Omeros Corporation Metastatic Melanoma Drug Product Portfolio
- 4.10.5 Omeros Corporation Recent Developments
- 4.11 NewLink Genetics Corporation
- 4.11.1 NewLink Genetics Corporation Company Information
- 4.11.2 NewLink Genetics Corporation Business Overview
- 4.11.3 NewLink Genetics Corporation Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 NewLink Genetics Corporation Metastatic Melanoma Drug Product Portfolio
- 4.11.5 NewLink Genetics Corporation Recent Developments
- 4.12 Morphotek, Inc.
- 4.12.1 Morphotek, Inc. Company Information
- 4.12.2 Morphotek, Inc. Business Overview
- 4.12.3 Morphotek, Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Morphotek, Inc. Metastatic Melanoma Drug Product Portfolio
- 4.12.5 Morphotek, Inc. Recent Developments
- 4.13 Millennium Pharmaceuticals, Inc.
- 4.13.1 Millennium Pharmaceuticals, Inc. Company Information
- 4.13.2 Millennium Pharmaceuticals, Inc. Business Overview
- 4.13.3 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Millennium Pharmaceuticals, Inc. Metastatic Melanoma Drug Product Portfolio
- 4.13.5 Millennium Pharmaceuticals, Inc. Recent Developments
- 4.14 Merck KGaA
- 4.14.1 Merck KGaA Company Information
- 4.14.2 Merck KGaA Business Overview
- 4.14.3 Merck KGaA Metastatic Melanoma Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Merck KGaA Metastatic Melanoma Drug Product Portfolio
- 4.14.5 Merck KGaA Recent Developments
5 Global Metastatic Melanoma Drug Market Scenario by Region
- 5.1 Global Metastatic Melanoma Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Metastatic Melanoma Drug Sales by Region: 2021-2032
- 5.2.1 Global Metastatic Melanoma Drug Sales by Region: 2021-2026
- 5.2.2 Global Metastatic Melanoma Drug Sales by Region: 2027-2032
- 5.3 Global Metastatic Melanoma Drug Revenue by Region: 2021-2032
- 5.3.1 Global Metastatic Melanoma Drug Revenue by Region: 2021-2026
- 5.3.2 Global Metastatic Melanoma Drug Revenue by Region: 2027-2032
- 5.4 North America Metastatic Melanoma Drug Market Facts & Figures by Country
- 5.4.1 North America Metastatic Melanoma Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Metastatic Melanoma Drug Sales by Country (2021-2032)
- 5.4.3 North America Metastatic Melanoma Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Metastatic Melanoma Drug Market Facts & Figures by Country
- 5.5.1 Europe Metastatic Melanoma Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Metastatic Melanoma Drug Sales by Country (2021-2032)
- 5.5.3 Europe Metastatic Melanoma Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Metastatic Melanoma Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Metastatic Melanoma Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Metastatic Melanoma Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Metastatic Melanoma Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Metastatic Melanoma Drug Market Facts & Figures by Country
- 5.7.1 South America Metastatic Melanoma Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Metastatic Melanoma Drug Sales by Country (2021-2032)
- 5.7.3 South America Metastatic Melanoma Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Metastatic Melanoma Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Metastatic Melanoma Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Metastatic Melanoma Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Metastatic Melanoma Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Metastatic Melanoma Drug Sales by Type (2021-2032)
- 6.1.1 Global Metastatic Melanoma Drug Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Metastatic Melanoma Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Metastatic Melanoma Drug Revenue by Type (2021-2032)
- 6.2.1 Global Metastatic Melanoma Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Metastatic Melanoma Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Metastatic Melanoma Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Metastatic Melanoma Drug Sales by Application (2021-2032)
- 7.1.1 Global Metastatic Melanoma Drug Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Metastatic Melanoma Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Metastatic Melanoma Drug Revenue by Application (2021-2032)
- 7.2.1 Global Metastatic Melanoma Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Metastatic Melanoma Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Metastatic Melanoma Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Metastatic Melanoma Drug Value Chain Analysis
- 8.1.1 Metastatic Melanoma Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Metastatic Melanoma Drug Production Mode & Process
- 8.2 Metastatic Melanoma Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Metastatic Melanoma Drug Distributors
- 8.2.3 Metastatic Melanoma Drug Customers
9 Global Metastatic Melanoma Drug Analyzing Market Dynamics
- 9.1 Metastatic Melanoma Drug Industry Trends
- 9.2 Metastatic Melanoma Drug Industry Drivers
- 9.3 Metastatic Melanoma Drug Industry Opportunities and Challenges
- 9.4 Metastatic Melanoma Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst